What's Happening?
CoRegen has received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application for CRG-150, a novel gene-edited regulatory T-cell (Treg) therapy. This clearance allows CoRegen to proceed with a first-in-human
Phase 1/2a clinical trial (NCT07730125) for patients with metastatic triple-negative breast cancer, metastatic hormone receptor-positive/HER2-negative breast cancer, or metastatic prostate cancer. The therapy involves collecting a patient's own Tregs through apheresis, then using CRISPR-Cas9 gene editing to disrupt the NCOA3 gene, which produces the SRC-3 protein. This reprogramming aims to alter the Tregs' function from suppressing immune responses to actively promoting an anti-tumor immune environment. Unlike many existing cell therapies, CRG-150 does not require lymphodepleting chemotherapy prior to infusion, and the edited cells are intended to reshape the tumor microenvironment and recruit the patient's existing effector immune cells to fight the cancer.
Why It's Important?
CRG-150 represents a significant shift in cancer immunotherapy by targeting the tumor's immune-suppressive mechanisms rather than directly attacking cancer cells or boosting killer T-cells. Regulatory T cells (Tregs) are often co-opted by tumors to create an immunosuppressive environment, allowing cancer to evade detection and destruction. By reprogramming these Tregs, CRG-150 aims to turn a component of the tumor's defense into an active participant in its destruction. This approach could be particularly impactful for solid tumors, which have proven challenging for other cell therapies due to physical and immune barriers. If successful, this strategy could offer a new therapeutic avenue for patients with advanced cancers who have exhausted other treatment options, potentially leading to more durable anti-tumor immunity and expanding the reach of immunotherapy beyond current limitations.
What's Next?
Enrollment for the Phase 1/2a clinical trial of CRG-150 is expected to open late in 2026, with plans to enroll up to 67 adults. The initial phase of the trial will primarily focus on establishing the safety of the therapy and identifying an optimal dose. Investigators will also closely monitor the persistence of the edited cells in the body, as this will be crucial for understanding the therapy's long-term potential. While preclinical mouse studies have shown promising results, the efficacy in human patients remains to be determined. The clinical protocol includes a long-term safety follow-up extending up to fifteen years, reflecting the FDA's stringent framework for genome-edited therapies. CoRegen's partnership with Lonza for manufacturing CRG-150 will be critical in ensuring consistent and high-quality cell product production for the trial.
Beyond the Headlines
The CRG-150 therapy introduces a fascinating ethical and biological question: can immune tolerance be selectively modulated within a tumor without compromising systemic immune tolerance throughout the body? Tregs are essential for preventing autoimmunity, and broadly disrupting their function could lead to severe autoimmune diseases. The animal studies suggest a localized effect, but human biology is more complex. This therapy also highlights the growing sophistication of gene editing, moving beyond simply 'fixing' faulty genes to 'reprogramming' cellular functions for therapeutic benefit. The distinction between targeting SRC-3 within cancer cells versus within Tregs is crucial for public understanding and avoiding misinterpretations of the therapy's mechanism. The success or failure of CRG-150 will not only impact cancer treatment but also inform future strategies for manipulating the immune system in other diseases, such as autoimmune disorders and chronic infections.
